Determining the biological limits to human longevity is more difficult than for most other species because humans are long-lived. Consequently, mortality data, such as from the U.S. vital statistics system, which have been available for a long time (relative to most epidemiological studies) and have large numbers of cases, including deaths reported to advanced ages, are important in studying human longevity -though care must be exercised in dealing with error in age reporting. Furthermore, it is unlikely that free-living humans can realize as much of their biological endowment for longevity as animals living in a highly controlled experimental environment. We examined changes, 1960 to 1990, in U.S. White male and female extinct cohort life tables and age at death distributions to (a) examine evidence for the effects of a biological life span limit in current U.S. mortality patterns and (b) produce lower bound estimates of that limit.
HPESTING whether U.S. mortality currently reflects bio-
A logical limits is difficult because of the length of human life spans and because the environment of human populations is under less control than animals in experimental studies, i.e., realized human life expectancy will be a smaller proportion of their biological potential because of environmental heterogeneity. Estimating human life span limits is also complicated by uncertainty about ages reported at death.
Consequently, biological life span limits are often studied using animal models. Carey et al. (1992) found for 1.1 million fruit flies that mortality reached a high but constant value after 90% had died -possibly due to the attrition of frail individuals. Curtsinger et al. (1992) found mortality reached a high constant value in Drosophila in genetically homogenous groups. Brooks et al. (1994) found the nematode C. elegans manifested a high constant mortality at late ages in wild populations. Kenyon et al. (1993) found modifying two genes doubled the life span in C. elegans, while leaving the variance of age at death unchanged.
Studies of human mortality produce similar results. In one (IPSEN, 1991; Vallin, 1993) , male mortality increased only 2.2% per year from ages 100 to 109; 3.0% for females. Another found male mortality increases of 8.8% per year of age from 75 to 84 dropped to 3.2% from 95 to 104; female mortality increases of 10.5% per year of age from 75 to 84 dropped to 2.5% from 100 to 109 (Lew and Garfinkel, 1990) . Analyses of Swedish and U.S. Medicare cohorts showed mortality increases slowing at late ages (Manton et al., 1981 (Manton et al., , 1986 as did charter Social Security beneficiaries, U.S. vital statistics (Bayo and Faber, 1985) , and insurance data used to form group annuity tables (Society of Actuaries, 1994) .
Mortality rates rising exponentially to late ages suggest the operation of life span limits. However, neither animal nor human studies show such exponential, Gompertzian increases in mortality. A possible reason is mortality selection. Data suggest selection strongly affects the distribution of health and function among survivors to age 85 + , i.e., ages where the Gompertz does not describe mortality. Marenberg et al. (1994) found, in male and female twins born 1886 to 1925, relative risks from coronary heart disease declined from 13-15 to 1 in middle age to 1.0 to 1 above 85. Decreased prevalences of genetically determined lung cancer (Sellers et al., 1990) , thyroid auto-antibodies (Mariotti et al., 1992) , apolipoprotein E-4 allele frequency (Louhija et al., 1994) , and the C4B*Q0 gene (Kramer et al., 1991 (Kramer et al., , 1994 were also found at late ages.
To directly analyze selection, longitudinal data with covariates are required. Analyses of the 34-year Framingham Heart Study follow-up, and the 9.5-year follow-up of the National Long Term Care Survey, showed mortality approaching a constant level above age 95 with deterioration of population risk factor values and function slowing about the same age. Thus, even with stochastically evolving state variables, selection slowed age increases in survivors' average mortality risk and health deterioration. Selection on clinical attributes affecting homeostasis to age 80+ were found by Bild et al. (1993) , Campbell et al. (1993) , and Perls etal. (1993) .
To test for life span limits without using a specific model of the age dependence of mortality requires large populations. In U.S. data there are concerns about the accuracy of ages reported at death. Recent studies, however, suggest data quality improved because of Social Security (starting in 1937) and Medicare (starting in 1966) requirements for age documentation to qualify for benefits (Kestenbaum, 1992) . Age reporting also likely improved as the education of elderly U.S. cohorts rose, e.g., the proportion of persons aged 85 to 89 with less than 8 years of schooling is projected to decline from 60%+ in 1980 to 10-20% in 2015 (Preston, 1992) .
A final difficulty is mathematically defining a test of whether human survival curves are becoming "rectangu-where D xc denotes deaths at age x for cohort c = 1870-1874, 1880-1884, or 1890-1894. Ungraduated estimates for age x were smoothed by a five-year moving average. Thus, accounting for the five birth years in each cohort and the five-year moving average used in smoothing, each graduated estimate of q xc is a function of 25 single year-of-age and time death counts. Graduated estimates for U.S. Whites are shown in Figure 1 .
The q x , c for the 1870-1874 cohorts are 34.2% at 100, 38.6% at 105, and 41.8% at 110. The 1880-1884 q XiC involve 1870-1874 cohort data above age 106. The 1890-1894 q xc involve data from the two older cohorts above age 96. Thus, q xc at late ages for the 1890-1894 cohort are biased upward by the older cohorts' experience. This should produce conservative life expectancy estimates for the youngest cohort. At age 90, where there is little bias, the q IC declined 24%, i.e., from 20.8% (1870-1874) to 15.8% (1890-1894).
In Table 1 are gender-specific estimates of q xc and e xc (life expectancy) at ages 85, 90, and 95, and the average q xc for 10-year age intervals.
The e 85 between the two younger male cohorts increased 0.4 years; 0.9 years for females. The e^ increased 0.5 years ( + 1 5 . 5 % ) across the three male cohorts; 0.9 years ( + 24.5%) for females. These increases are lower bound estimates of e xc changes because the 1890-1894 cohort uses the older cohorts' experience above age 96.
The annual percent increase in mortality estimated for 10-year age intervals from 70-79 to 100-109 (age 110 in 1990 is reached only by the 1870-1874 cohort) is similar to the Gompertz exponential parameter. If this parameter is constant, or increases, a fixed life span limit is implied. If it decreases with age, a constant mortality level may be reached, implying that there is no fixed life span limit. For the 1890-1894 male cohort, mortality increased 6.8% per year from ages 70 to 89; 8.5% for females. For the 1880 to 1884 male cohort, mortality increased 6.2% from 80 to 99; 7.0% for females. For the 1870-1874 male cohort, mortality increased 2.8% from 90 to 109; 4.0% for females. If a common Gompertz determined gender-specific mortality at late ages in all three cohorts, the percent increases would be constant. Declines in the age rate of increase of mortality for male and female cohorts are inconsistent with a fixed life span limit.
A stochastic life span limit might be defined as the age by which e xc drops below, say, a year. For the stochastic limit to be at age x, assuming q x is constant at later ages, requires q x 2* 0.632. Kisker (1986, 1990) suggest a limit of 110 years for cohorts born before 1870. No estimate in Table  2 reaches the stochastic limit, i.e., q, 10 never exceeds 0.632.
In Table 2 the most reliable estimates are for both sexes. 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 \- (NCHS) q 110 is lowest -38.2%. The 1980 Social Security Administration (SSA) estimate is highest, 55.3%. Kannisto's (1994) estimate for 14 countries in 1980 -1990 , and Kestenbaum's (1992 1987 Medicare estimate, are both 49.4%. In the 1990-1992 IPSEN study (779 centenarians; about 600 deaths), q 110 was 48.9%. Cross-sectional q,'s are higher than cohort estimates if mortality is declining. They may also be elevated if a year with influenza activity is selected. The q no for the longitudinal Cancer Prevention Study (CPS) 1960-1987 (969 deaths above 100) was 40.8%. In the ungraduated group annuity experience for 1986 to 1990 (based on data from 11 large insurance companies; age reporting for insured persons is considered excellent) used to construct the 1994 Group Annuity Mortality Table, both male and female rates reached 25% about age 95 and then fluctuated about that value (Society of Actuaries, 1994).
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For simulations we heed "consensus" q, estimates. Thus, we averaged the q x for both sexes for every fifth year, from age 65 to 90, in the 1969 -1971 (NCHS, 1975 ) and 1979 -1981 (NCHS, 1985 U.S. life tables and fit a function to them. This produced a q 100 (estimator A, Table 2 ) of 30.0% and a q 110 of 47.0%, with mortality increasing 4.6% per year. The average of 7 q 100 estimates (SSA [9, 10] and NCHS [1] ) estimates were excluded because they were mathematically smoothed at late ages) was 33.3%, and 6 estimates of q 110 , 45.3%, with a smaller annual increase of 3.1% (estimator B).
The higher annual percent increase for estimator A produces lower estimates of life span limits than estimator B. Estimator A was used to extrapolate q x s to age 110 + .
Cross-sectional Changes in Age at Death Distributions
The 1960 to 1990 U.S. mortality data were also analyzed by examining changes in the age at death distribution Manton, 1984a, 1984b; Rothenberg et al., 1991) . This involves different assumptions, i.e., instead of estimating the late mortality experience of younger cohorts we assume differences in birth cohort size have little effect on late age mortality.
We determined the age by which a fixed proportion of deaths occurs from U.S. age at death distributions for each year 1960 to 1990. Though those ages are affected by birth cohort size and age-specific mortality, mortality effects dominate at late ages if cohort size differences are modest. In Denmark, Norway, and Sweden, 0.0 to 15.6% of centenarian growth was due to cohort size differences, i.e., 84.4 to 100% was due to mortality changes; 51 to 75% of centenarian growth was due to mortality changes from age 80 to 100 (Vaupel and Jeune, 1994) . In the U.S. the cohort born in 1990 was 121.3% larger than the cohort born in 1900. The proportion surviving from 65 to 100 increased 627% from the 1900 to the 1990 male cohort life tables; 390% for females (Social Security Administration, 1992) . Thus, mor- •q(x,x+10)= ltality changes from 65 to 100 had 5.2 times more effect on the number of males surviving to 100 than initial cohort size; for females, mortality effects were 3.2 times larger. Figure 2 depicts the 25th to the 99.99th percentiles of the 1960 to 1990 age at death distributions for deaths above age 65.
Increases are similar in the upper tail, e.g., the 75th percentile age increased 3.3 years; the 99.9th percentile 3.0 years. This can be compared to estimates of life endurancy (99.999th percentile of deaths at all ages in life tables calculated from Medicare data) which increased 4 years (from 109 to 113) from 1960 to 1990 for females; 3 years (108 to 111) for males (Social Security Administration, 1992) . Table 3 compares changes 1960 to 1990 in the percentiles of the age at death distribution to the changes required to reach life span limits of 120 and 130 years.
The observed change is a fraction of that required to reach either limit: 4-19% for 120 years, 3-12% for 130 years. Thus, if the mean life span potential was 120 (or 130) years, limits on U.S. mortality improvements would currently be negligible if individual life span potential is narrowly distributed around 120 years, e.g., from 110 to 130. The life span limit must be at least as high as the highest documented age achieved, i.e., 121.5 years (a French female). In the U.S., ages of 126 (male; SSA records; female; Kautzky, 1995), 124 (male; Bortz, 1991) , and 123 (female; Allegood, 1994) have been reported. Though these reports are incompletely documented, if only one were accurate the empirical lower bound to the life span limit would be 2 to 5 years higher.
Limits may be gender specific. For both genders the ages for all percentiles increased 1960 to 1990. Female change is larger (3.3 to 4.0 years from the 50th to 99.5th percentiles), and to higher ages -even though White females live longer than White males. The largest female increase (4.0 years) was for the 90th percentile. For males the increase was the same (2.5 years) for the 95th, 99th, and 99.5th percentiles.
The 1960-1962 and 1988-1990 data in Table 4 show changes in the age distribution of deaths above 85, e.g., a 12.9% decline in the proportion of deaths occurring at age 85-89, and proportionately more deaths at age 90 + . To test whether changes at late ages (e.g., 105 to 109) are significant, death counts were treated as random variables (Deming and Stephan, 1941; Cassel et al., 1977) , and Mests calculated for the proportions in an age class at two times.
Shifts from 85-89 to latter ages are significant. The mean age for deaths over 85 increased significantly, 1.2 years -0.8 years for males and 1.4 year for females. The standard deviation also increased significantly, 0.64 years -0.47 years for males and 0.65 years for females, i.e., there is no compression of the upper tail of the age at death distribution from 1960 to 1990 for either gender. The decline for males at 110+ (from 29 deaths in 1960-1962 to 10 in 1988-1990 ) is due to improvements in the accuracy of reported late ages, 
Notes on Sources:
'NCHS (1985) U.S. decennial life tables for 1979-81, U.S. White population -age 100 as reported; age 110 extrapolated from age 109 using NCHS's extrapolation formula.
" Lew and Garfinkel (1990) , Cancer prevention study 1960-1987 -age 100 interpolated from 95-99 and 100-104; age 110 extrapolated from 100-104 and 105-109. Approximately 97% of the study population was White.
'Data in Figure 1 for 1890-1894 cohort, U.S. White population. "Data in Figure 1 for 1880-1884 cohort, U.S. White population. 'Data in Figure 1 for 1870-1874 cohort, U.S. White population. ' Vallin (1993) , data from IPSEN study 1990-92 -age 100 as reported; age 110 extrapolated from 100-104 and 105-108. eKestenbaum (1992), Medicare mortality 1987 -age 100 is average of 99.5 and 100.5; age 110 is estimated from age 107.5-112.5 assuming reported value for 109.5 + is constant above age 109.5 -figures by sex at age 100 are for U.S. Whites; figures for both sexes at ages 100 and 110 are for total U.S. population.
h Kannisto (1994) , Centenarian life table, 1980-1990, composite of 14 countries' data (Japan plus 13 European countries) -age 100 as reported; age 110 estimated from 109-111 (males) and 108-112 (females; both sexes).
'JSSA(1992), Life tables for 1980 and 1990 (includes both U.S. White and non-White populations) -age 100 and 110 as reported for males and females; both sexes generated as weighted average of male and female q,'s using /,'s as weights. Mortality is extrapolated ( + ) by SSA above age 95 at a fixed 5% (male) or 6% (female) per year increase in q,.
'Data from eq. [1] for q\ at age 100 and 110. 'Average of empirical, non-model based estimates for age 100 (Sources 2, 3, 4, 5, 6, 7, 8) and age 110 (Sources 2, 4, 5, 6, 7, 8). -= not available.
i.e., deaths in 1960-1962 are from pre-1870 cohorts . The female change at 110+ is not significant.
Adjusting Age at Death Distributions for Cohort Size
To refine analyses of the 1960 to 1990 age at death distributions, we adjusted for cohort size differences using estimates of U.S. population growth. This eliminates the assumption that cohort size effects are small relative to mortality effects and substitutes the assumption that we can accurately estimate the initial size of elderly cohorts. From 1960 to 1990, the U.S. elderly population increased an average of 1.5% per year (U.S. Bureau of the Census, 1974 Census, , 1993 , i.e., in year y, the cohort population surviving to age 65, /«(y), is 1.5% smaller than in year y + 1. Cohort size at age x (in 1975, the midpoint of was calculated as c, = c,., x .985°+<*-«vio) (10 is a scale factor estimated from the data). This suggests the U.S. centenarian population grew 7% per year, e.g., cjc m = 1.070; c, 03 /c lw = 1.075. Vaupel and Jeune (1994) found centenarian populations grew 7.4% per year 1960 to 1990 in countries with reliable data. Kestenbaum's (1992) 1987 estimate of 22,600 centenarians and Siegel and Passel's (1976) estimate of 3,300 centenarians for 1960 implies an annual growth of 7.2% for the U.S. centenarian population 1960 to 1987. A growth rate of 7.0% was estimated for the 1870-1874 and 1880-1884 cohorts (Whites, both sexes) in Section II. Thus, the c,s are consistent with two U.S. estimates (Siegel and Passel, 1976; Kestenbaum, 1992 ; and the three extinct cohorts) and estimates of centenarian population growth in other developed countries (Vaupel and Jeune, 1994) .
The life table survival function is adjusted for population growth,
4*(0) = f, x c,,
where y is set to 0 for 1975. The ! x s were calculated from estimator A q x s (Table 2) for ages 65 + , using a quadratic (i.e., a linear first-difference) function, q* + . = q* + .0004 (x-65) + 0.0012.
Since the q x s used to estimate this function were not the lowest in years at age 75; 5.6 years at 85; and 3.3 years at 95 -within ± . 2 years of e, averages for the NCHS 1969 NCHS -1971 NCHS and 1979 NCHS -1981 life tables.
To examine the behavior of q x as it progressed from the current empirical mortality schedule (q x ) to the theoretical limiting mortality schedule (say, q j , we needed to (a) generate q,s, and (b) select the number of years it takes q, to reach q x . Setting these two factors will determine if, for these assumptions, we should observe certain trends in the q, as they move to the assumed limit.
The q x s were calculated by multiplying q, by the fraction of life lived by age x (relative to the assumed maximum life span) raised to a power k which determines the degree of change at each age as the assumed maximum life span is approached, i.e., q. = q* x I.
(2)
This function assumes that, as the distribution of life spans for individuals is approached by the empirical age at death distribution, smaller proportions of deaths occur at young ages; larger proportions at late ages. If there is a fixed distribution of life spans, the proportion of a cohort surviving to x is limited, with decreasing proportions living to x + 1 , etc. The larger the value of k the higher the life expectancy produced by the q x . For k = 2, e^ = 24.6 years; fork = 3, egj = 28.5 years; and for k = 4, e^ = 32.0years. In the evaluation below, to be conservative, we selected the lowest value of k consistent with current mortality patterns, assuming that the limit is achieved in 90 years. Other estimates of k could have been used if different age-specific mortality rate declines were assumed, or changes were allowed to occur over a longer period of time.
With k set at 2, q x s at age 111-115 are not much lower than q x s for the 1880-1884 cohort, i.e., the 1880-1884 q 110 (41.3%) is 27.5% higher than q 110 (32.4%). The q 1I0 (38.2%) for 1979-1981 U.S. life tables is only 17.9% higher than q,, 0 -The & a calculated from q x is 24.6 years; 16.2 years at 75; 9.8 years at 85; and 5.6 years at 95. The differences between the e x s calculated from q x (with k = 2) and q x are 8.6, 6.5, 4.2, and 2.3 years at ages 65, 75, 85, and 95. Another estimate of U.S. life expectancy limits is 85 years; 90 years eliminating all circulatory diseases, diabetes, and cancer deaths (Olshansky et al., 1990) . Those estimates assume a reduction of 70% in q x s at all ages. The form of (2) does not require q x to be a constant proportion of q x -an assumption we felt was unrealistic. With k = 2, q 75 is 32.0% of q 75 (68.0% less); q 95 is 51.4% of q 95 (48.6% less); and q 110 is 68.9% of q 110 (31.1% less). Thus, for k = 2 an e« of 24.6 years (implying an e 0 near 89 years) is generated with less than a 70% reduction in q x s above age 72 (e.g., 31.1% at 110) using a conservative estimate of the annual age change (4.6%) in mortality (the empirical average was 3.1% in Table 2 ; it was assumed to be 0.0 at age 112 in 1994 actuarial estimates; Society of Actuaries, 1994) .
The trajectory of the q x with k = 2 is consistent with Lee and Carter's (1992) estimates that U.S. mortality declined 1.0-1.2% per year for ages 65 to 85 from 1900 to 1989. Ahlburg and Vaupel (1990) report declines of 1% to 2% per year at most ages 1968 to 1982; Kannisto et al. (1993) reported declines of 0.5% per year for centenarians in 14 countries 1960 to 1989; Vaupel and Lundstrom (1994) suggest a decline of 0.52% per annum for Swedish female centenarians 1960 to 1989. Convergence of q x with q x , with k = 2 assuming convergence requires 90 years, generates q x declines of 1.58% per year at 65; 1.26% at 75; 0.99% at 85; 0.74% at 95; and 0.52% at 105, i.e., age-specific reductions consistent with the cited studies.
By varying the time to convergence (from 90 years) and k we can examine how the age at death distribution, f x , changes as q x approaches q x . The estimate of q x at date y is designated q*(y). Assuming q x is reached in 90 years, and k = 2, q x *(y) was calculated, q?(y) = 132.5 x 132.5 y>45k
To adjust f x for cohort size, death counts are needed for each x and y. Calculating the cross-sectional age at death distribution, ff(y), requires renormalizing d*(y) to 1.0, i.e.,
133
= d x *(y)/Sd*(y),
where d x *(y) = / x *(y) q*(y). This is analogous to calculating the life table distribution of deaths (from age 65) from cl x (which is determined by q x ), or from q x :
Because 4, = q*(0), the starting distribution (y = 0) is 133 which differs from r\ only by the cohort reduction factors, c x . Using these relations, we first examined changes in the life table age at death distributions for q x (i" x ) and q x (f x ). f*(0) is calculated from q*(0) = q x . Differences between f x *(0) and ? x reflect both initial cohort size (c x s) and survival differences. If all cohort sizes and prior mortality were the same, then f*(0) = ? x and the upper limit to the age at death distribution is f x . Differences between ? x and f x are summarized by differences in e x s, e.g., e M -e M = 8.6 years. For every million deaths above 65, f\ yields 3 above 115 and none above 118; f x yields 1,033 above 115, 39 above 120, 3 above 123, and none above 125. Thus, no one, out of a million deaths, has much chance of reaching the absolute limit of 132.5 with q x where k = 2. There is a likelihood that someone reaches the stochastic "limit" of 123.
Setting k = 0 illustrates the effect of biological limits on the age at death distribution, i.e., q*(y) = q x = q x , for all y 5= 0. Here, differences in f*(y) are due to the initially larger 6 x s for older cohorts which cause the age by which a proportion of deaths occurs to increase linearly for 30 years before slowing.
If mortality is improving, age differences between pairs of percentiles are constant. Age increases for the 90th (or above) percentile of f x are not linear after 30 years due to differences in the c x between older (up to 7%) and younger cohorts (1.5%). If mortality stops improving, it takes 20 years for the age for each percentile in f x to stop increasing; nonlinear changes begin in 10 years. Thus, if U.S. mortality reached a biological limit, changes in f x would take 10 years to show nonlinearity -even if cohort sizes increased.
To affect f x , the distributions of individual life spans have to overlap more than ? x and f x where the mean life span is 8 or 9 years above the mean of the age at death distribution. A life span limit requires that 50 to 100% of deaths above age 85 could not be delayed, i.e., most persons above 85 realize their longevity potential; f x implies 1 in a million persons lives to age 124 (in 1990 there are 1.6 million U.S. deaths above 65). The overlap of f x and f x is smaller than 50% -implying life span limits do not currently affect mortality. This lack of effect is for k = 2 and a life expectancy of about 89 years. If k = 3, the theoretical limit to life expectancy is about 93 years and the effects of the restrictions take longer to emerge.
Changes in Cause-Specific Age at Death Distributions
If there is a fixed life span distribution, there should be rapid age increases in the proportions of deaths from causes occurring at ages far from the limit -with little age change in percentiles for diseases causing deaths close to the limit. If the limit is due to senescence, and the mean age at death for each cause increases, cause-specific distributions should become increasingly similar, i.e., a general process of senescence reduces homeostasis so the triggering threshold for any cause declines with age. When homeostasis is sufficiently weak, any biological insult causes death, forcing cause-specific age of death distributions to converge, i.e., the average age at death for each cause nears the life span limit. Examining specific causes of death is also useful because, if there is error in age reporting, unless that error is correlated with specific causes, it will tend to raise the mean age at death from all causes, and be biased toward expressing a senescent effect. If causes operate independently (i.e., are not governed by a single limiting process), or are operating far from the limiting distribution, then changes in their distributions will not be restricted.
Changes in the U.S. cause of death distributions at late ages can be examined relative to past mortality trends. Agestandardized heart disease and stroke mortality rates declined 53.0% and 70.4%, respectively, from 1950 to 1992; agestandardized cancer mortality rates increased 6.2%. This shifted the proportion of deaths in the age-standardized distribution of deaths from 36.5% to 28.6% for heart disease; from 10.5% to 5.2% for stroke; from 11.3 to 23.6% for cancer. The effects of these changes at later ages are of interest because cancer and senescence may depend on similar mechanisms (e.g., Cutler and Semsei, 1989) . Above 85, heart disease and stroke mortality rates declined 28.8% and 47.6%, respectively -cancer mortality rates increased 23.2%. Above 85, the proportion of deaths due to heart disease declined from 45.3 to 43.5%; for stroke from 14.8 to 10.5%. For cancer it increases from 7.2 to 11.9%. Thus, cause-specific changes for younger ages hold for ages 85 + . For 50,000 persons aged 75 + followed 1960 to 1987 (Lew and Garfinkel, 1990) , cancer caused 16% of deaths at age 75-79 but only 7.1% (male) and 4.6% (female) at 95-99. This shows the decline in cancer mortality with age -but not the persistence of the age decline over time. Thus, we examined changes 1962 to 1990 in the distributions of ages at death for eight causes above age 85. In addition to heart disease, cancer, and stroke, we selected conditions (e.g., diabetes; nephritis and nephrosis; lung disease) that may trigger lethal events, or acute morbid sequelae of other agerelated failures (e.g., changes in immunological response [pneumonia, septicemia] ). Distributions of death counts for each cause for five-year age categories from 85-89 to 110 + for 1962-1964 and 1988-1990 are in Table 5 . Mests were calculated for differences in the proportion of deaths in each age category and for changes in the mean and standard deviation of the cause-specific distributions.
The largest declines in the proportion of deaths occurring at age 85-89 (and the greatest increases above 90) are for septicemia (-17.7%) and diabetes (-16.0%). Cause-specific mean ages at death increased 0.5 to 1.6 years. Standard deviations of cause-specific age distributions increased 7.1% (chronic lung disease) to 29.5% (diabetes). Thus, all causespecific distributions showed increases in the mean and standard deviation of ages at death -neither would be expected if all causes were limited by a common process. For age 100-104 the proportion of deaths due to heart disease changed little (50.5 vs 50.3%). Stroke declined from 15.7 to 9.3%. Cancer increased from 2.5 to 3.9%. Thus, for age 100-104 declines in stroke, and increases in cancer, mortality continue.
In Tables 6 and 7 are cause-specific results for males and females.
Male cause-specific means (Table 6 ) increased 0.6 to 1.3 years; female means 0.2 to 1.5 years. Male standard deviations increased 9.1% (lung disease) to 32.1% (septicemia). Female standard deviations increased 2.5% (nonsignificant) for lung disease to 30.3% for diabetes (significant; with a 1.5-year increase in the mean). Female declines in the proportion of deaths at age 85-89 are generally larger than for males. Thus, the pattern of increases in all means and standard deviations shown for all deaths is found for males and females separately. At age 100-104 for males the proportion of heart disease (49.7 to 47.7%) and stroke (15.2 to 8.1%) deaths declined, whereas cancer (3.3 to 5.4%) increased. For females heart disease deaths did not change (50.9% at both times). Stroke deaths declined significantly (from 15.9 to 9.6%) while cancer (2.2 to 3.5%) increased. Thus, the male and female cause-specific distributions of deaths at age 100-104 have a similar structure.
Cohort Size and Mortality Effects on the Maximum Expected Age at Death
Empirical analyses of life span are limited because we only observe survival outcomes for small cohorts born far in the past. To estimate the maximum age at death expected in a population, x^, we must combine the population's size at birth and a life table describing its mortality. Below we identify 25 combinations used to assess the dependence of x m ,, on those two factors. The letters in Table 8A indicate which of five cohort (or modified cohort) life tables, and numbers which of five cohort sizes, were used in calculations. The first four sizes represent actual birth cohorts, e.g., 4.3 million persons were born in the U.S. in 1961 -70.5 times more than the 61,000
Swedes born in 1910. If both cohorts are subject to the same life table, 70.5 times as many persons in the U.S. cohort would survive to a given age. Furthermore, the age for which there is a 50% chance of observing at least one survivor would be higher, holding mortality constant, for the larger birth cohort. We determined the age at which the last death in a population is expected (at a given probability) for these cohort sizes and life tables.
The / x s used were from 1910, 1960, and 1990 U.S. cohort life tables (SSA, 1992) . Estimates of late age survival are conservative for conditions a or b because SSA's q ll0 estimates are the highest in In Table 8B are age-specific numbers of survivors expected for cohort sizes 1-4 using 1910 and 1960 U.S. cohort life tables (a,b). The expected number of survivors to age x is equal to the expected number of deaths at or above x. For a Poisson distribution, \ ma is the age at which the expected number of survivors is 0.693 with a probability of 50% that the last death occurs above this age. If mortality is improving. XmM m Table 8B should exceed the highest ages yet observed because the 1910 cohorts are only aged 85 in 1995 (e.g., age 110 is reached in 2020). Currently observed maximum ages at death come from smaller cohorts with higher early mortality.
The expected number of male deaths at 110 + in the 1910 Swedish cohort with the 1910 U.S. cohort life table (a) is 0.6, the probability of one or more deaths at 110 + is 45%. Using the 50% rule, *"," is 109. This can be compared to 7.7 male deaths at 110 + expected in the 1910 French cohort, 27 for the 1910 U.S. cohort, and 43 for the 1960 U.S. cohort. Since the oldest Swede observed to date was 111, this suggests that these estimates (which apply to future dates) are conservative. We can also determine the uncertainty of the probability that at least one person reaches age x. The 14 male deaths at 110+ expected for the 1910 Swedish cohort with the 1960 U.S. cohort life table (b) has a standard error of 3.75, i.e., between 6.5 and 21.5 deaths are expected with 95% confidence. The Mest of the hypothesis that no deaths occur above 110 is 3.74; i.e., less than a 1 in 1,000 chance. effects of the mean and variance of the potential life span distribution, and changes in cohort size, are not considered in estimates of human life expectancy limits of 85 years (e.g., Olshansky et al., 1990) . It would take extreme conditions (e.g., a large genetically determined variance for life span) for life expectancy to be limited to 85 years. Our analyses had two goals. One was to test if biological limits constrained U.S. mortality reductions 1960 to 1990. The data do not support this hypothesis. Second, we estimated fixed and stochastic limits. We found that current estimates of life expectancy limits could be exceeded under plausible scenarios (e.g., mortality reductions were not proportional over age).
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